Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Sep 13, 2016
Arbutus' Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award

Aug 10, 2016
Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference

View all »Events & Presentations

Aug 16, 2016
2016 Wedbush PacGrow Healthcare Conference

Jul 17, 2016
2016 Controlled Release Society Conference